Scholarlink

Abstract Purpose <p>Proton therapy (PT) offers dosimetric advantages over conventional X-ray–based radiotherapy (XRT), aiming to reduce toxicity and better spare healthy tissues. The Agency for Health Quality and Assessment of Catalonia (AQuAS), commissioned by the Spanish Ministry of Health, conducted a Health Technology Assessment to evaluate the safety and clinical effectiveness of PT for cancer indications not yet approved for PT in Spain. This article summarizes the main findings regarding PT’s safety and clinical performance in adults compared with XRT.</p> Methods <p>The assessment was based on a systematic review of primary studies published between 2012 and 2024, following Cochrane methodological standards, PRISMA guidelines, and the GRADE approach. Eligibility criteria were defined using the PICO-DT framework, focusing on adult cancer patients, comparative study designs, and primary outcomes including serious adverse events, mortality, overall survival, and progression-free survival. Risk of bias was evaluated with RoB 2.0 and ROBINS-I depending on study design. Searches covered major biomedical databases.</p> Results <p>Of 6958 records screened, 76 were included (five randomized trials and 71 observational studies) across 16 tumour types. Overall, evidence certainty was low or very low, limited by few randomized trials, methodological concerns, and heterogeneity. For some indications, including leptomeningeal metastases, lung cancer, and anal cancer, evidence suggests that PT may be equivalent or superior to XRT, although certainty remains limited.</p> Conclusions <p>PT shows variable, cancer-specific results and does not consistently outperform XRT. Some indications appear promising, but substantial evidence gaps persist, emphasizing the need for high-quality comparative studies and systematic clinical data collection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evidence-based indications for proton therapy in adults determined using the GRADE approach

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月20日

查看全文
  • Carolina Moltó-Puigmartí,
  • Jordi Giralt,
  • Lucía Alonso García,
  • Clara Pons Duran,
  • Carles Gomà,
  • Sara Pedraza Fernández,
  • Maria-Dolors Estrada Sabadell,
  • Rosa Maria Vivanco Hidalgo

摘要

Abstract Purpose

Proton therapy (PT) offers dosimetric advantages over conventional X-ray–based radiotherapy (XRT), aiming to reduce toxicity and better spare healthy tissues. The Agency for Health Quality and Assessment of Catalonia (AQuAS), commissioned by the Spanish Ministry of Health, conducted a Health Technology Assessment to evaluate the safety and clinical effectiveness of PT for cancer indications not yet approved for PT in Spain. This article summarizes the main findings regarding PT’s safety and clinical performance in adults compared with XRT.

Methods

The assessment was based on a systematic review of primary studies published between 2012 and 2024, following Cochrane methodological standards, PRISMA guidelines, and the GRADE approach. Eligibility criteria were defined using the PICO-DT framework, focusing on adult cancer patients, comparative study designs, and primary outcomes including serious adverse events, mortality, overall survival, and progression-free survival. Risk of bias was evaluated with RoB 2.0 and ROBINS-I depending on study design. Searches covered major biomedical databases.

Results

Of 6958 records screened, 76 were included (five randomized trials and 71 observational studies) across 16 tumour types. Overall, evidence certainty was low or very low, limited by few randomized trials, methodological concerns, and heterogeneity. For some indications, including leptomeningeal metastases, lung cancer, and anal cancer, evidence suggests that PT may be equivalent or superior to XRT, although certainty remains limited.

Conclusions

PT shows variable, cancer-specific results and does not consistently outperform XRT. Some indications appear promising, but substantial evidence gaps persist, emphasizing the need for high-quality comparative studies and systematic clinical data collection.